NSCLC肿瘤及癌旁组织CD4~+和CD8~+T细胞PD-1的表达及意义
|
摘要
目的 探讨非小细胞肺癌(NSCLC)肿瘤及癌旁组织CD4~+和CD8~+T细胞上程序性死亡分子-1(PD-1)的表达及意义。方法 采用流式细胞术检测79例NSCLC患者肿瘤组织及78例NSCLC患者癌旁组织中CD4~+和CD8~+T细胞上PD-1的表达百分比,并分析其与NSCLC患者临床病理特征相关性。结果 肿瘤组织PD-1~+细胞占所有细胞百分比显著高于癌旁组织,差异有统计学意义(P<0.01)。肿瘤组织CD4~+和CD8~+T细胞表达水平显著高于癌旁组织,差异有统计学意义(P<0.01)。肿瘤组织CD4~+和CD8~+T细胞上PD-1表达水平显著高于癌旁组织,差异有统计学意义(P<0.01)。肿瘤>3 cm患者CD4~+和CD8~+T细胞上PD-1表达水平高于肿瘤≤3 cm患者,差异有统计学意义(P<0.05)。肺鳞癌患者CD8~+T细胞上PD-1表达水平高于肺腺癌患者,差异有统计学意义(P<0.05),而肺鳞癌患者CD4~+T细胞上PD-1表达水平与肺腺癌患者间差异无统计学意义(P>0.05)。PD-1表达在不同性别、年龄、病理分期、有无淋巴结转移间差异无统计学意义(P>0.05)。结论 NSCLC患者肿瘤组织CD4~+和CD8~+T细胞上PD-1表达水平明显高于癌旁组织,并与肿瘤大小具有相关性,可能为肺癌的研究提供参考。
Objective To explore the expression and significance of programmed death-1(PD-1) on CD4~+ and CD8~+T cells in tumor tissues and adjacent tissues of patients with non-small cell lung cancer(NSCLC). Methods The expressions of PD-1 on CD4~+ and CD8~+T cells in the tumor tissues of 79 NSCLC patients and the adjacent tissues of 78 NSCLC patients were detected by flow cytometry analysis, and the correlations between PD-1 expressions and clinicopathological characteristics of NSCLC patients were analyzed.Results Compared with adjacent tissues,the expression level of PD-1~+ cells in tumor tissues was significantly higher statistically(P<0.01).The expression level of CD4~+ and CD8~+T cells in tumor tissues was significantly higher statistically(P<0.01).The expression level of PD-1 on CD4~+ and CD8~+T cells in tumor tissues was significantly higher statistically(P<0.01).The expressions of PD-1 on CD4~+ and CD8~+T cells in patients with tumor diameter >3 cm were higher than those with tumor diameter≤3 cm,the difference was statistically significant(P<0.05).The expressions of PD-1 on CD8~+T cells in patients with lung squamous cell carcinoma were higher than those with lung adenocarcinoma, and the difference was statistically significant(P<0.05), while the expressions of PD-1 on CD4~+T cells were not statistically significant(P>0.05).The expressions of PD-1 were not related to the gender, age, pathologic stages and lymph node metastasis(P>0.05).Conclusion The expression level of PD-1 on CD4~+ and CD8~+T cells in tumor tissues is significantly higher than that in adjacent tissues and correlated with tumor size, which may provide a reference for research of lung cancer.
Objective To explore the expression and significance of programmed death-1(PD-1) on CD4~+ and CD8~+T cells in tumor tissues and adjacent tissues of patients with non-small cell lung cancer(NSCLC). Methods The expressions of PD-1 on CD4~+ and CD8~+T cells in the tumor tissues of 79 NSCLC patients and the adjacent tissues of 78 NSCLC patients were detected by flow cytometry analysis, and the correlations between PD-1 expressions and clinicopathological characteristics of NSCLC patients were analyzed.Results Compared with adjacent tissues,the expression level of PD-1~+ cells in tumor tissues was significantly higher statistically(P<0.01).The expression level of CD4~+ and CD8~+T cells in tumor tissues was significantly higher statistically(P<0.01).The expression level of PD-1 on CD4~+ and CD8~+T cells in tumor tissues was significantly higher statistically(P<0.01).The expressions of PD-1 on CD4~+ and CD8~+T cells in patients with tumor diameter >3 cm were higher than those with tumor diameter≤3 cm,the difference was statistically significant(P<0.05).The expressions of PD-1 on CD8~+T cells in patients with lung squamous cell carcinoma were higher than those with lung adenocarcinoma, and the difference was statistically significant(P<0.05), while the expressions of PD-1 on CD4~+T cells were not statistically significant(P>0.05).The expressions of PD-1 were not related to the gender, age, pathologic stages and lymph node metastasis(P>0.05).Conclusion The expression level of PD-1 on CD4~+ and CD8~+T cells in tumor tissues is significantly higher than that in adjacent tissues and correlated with tumor size, which may provide a reference for research of lung cancer.
引文
[1] Sunshine J,Taube J M.PD-1/PD-L1 inhibitors[J].Curr Opin Pharmacol,2015,23:32-8.
[2] Chen L,Han X.Anti–PD-1/PD-L1 therapy of human cancer:past,present,and future[J].J Clin Invest,2015,125(9):3384-91.
[3] Tumeh P C,Harview C L,Yearley J H,et al.PD-1 blockade induces responses by inhibiting adaptive immune resistance[J].Nature,2014,515(7528):568-71.
[4] 李汉忠,张玉石,郑国洋.肿瘤免疫治疗:回顾与展望[J].协和医学杂志,2018,9(4):289-94.
[5] 吴圣,邵婧怡,王芳,等.PD-L1和PD-1在胃癌组织中的表达及其临床意义[J].安徽医科大学学报,2015,50(6):821-5.
[6] Siegel R L,Miller K D,Jemal A,et al.Cancer Statistics,2015[J].CA,2015,65(1):5-29.
[7] Chen D,Mellman I.Oncology meets immunology:the cancer-immunity cycle[J].Immunity,2013,39(1):1-10.
[8] 吕淑贞,李艳萍,赵霞,等.乳腺癌组织PD1、PDL1表达变化及其与患者临床病理参数和预后的关系[J].山东医药,2018,58(28):28-31.
[9] 张锋,韦海涛,王作培,等.食管鳞癌组织中程序性死亡分子1表达变化及意义[J].山东医药,2016,56(26):41-3.
[10] 周莉,张冠男,王琳,等.非小细胞肺癌患者外周血PD-1表达水平及淋巴细胞亚群分析[J].中国肿瘤生物治疗杂志,2016,23(3):413-5.
[11] Huang A C,Postow M A,Orlowski R J ,et al.T-cell invigoration to tumour burden ratio associated with anti-PD-1 response[J].Nature,2017,545(7652):60-5.
[2] Chen L,Han X.Anti–PD-1/PD-L1 therapy of human cancer:past,present,and future[J].J Clin Invest,2015,125(9):3384-91.
[3] Tumeh P C,Harview C L,Yearley J H,et al.PD-1 blockade induces responses by inhibiting adaptive immune resistance[J].Nature,2014,515(7528):568-71.
[4] 李汉忠,张玉石,郑国洋.肿瘤免疫治疗:回顾与展望[J].协和医学杂志,2018,9(4):289-94.
[5] 吴圣,邵婧怡,王芳,等.PD-L1和PD-1在胃癌组织中的表达及其临床意义[J].安徽医科大学学报,2015,50(6):821-5.
[6] Siegel R L,Miller K D,Jemal A,et al.Cancer Statistics,2015[J].CA,2015,65(1):5-29.
[7] Chen D,Mellman I.Oncology meets immunology:the cancer-immunity cycle[J].Immunity,2013,39(1):1-10.
[8] 吕淑贞,李艳萍,赵霞,等.乳腺癌组织PD1、PDL1表达变化及其与患者临床病理参数和预后的关系[J].山东医药,2018,58(28):28-31.
[9] 张锋,韦海涛,王作培,等.食管鳞癌组织中程序性死亡分子1表达变化及意义[J].山东医药,2016,56(26):41-3.
[10] 周莉,张冠男,王琳,等.非小细胞肺癌患者外周血PD-1表达水平及淋巴细胞亚群分析[J].中国肿瘤生物治疗杂志,2016,23(3):413-5.
[11] Huang A C,Postow M A,Orlowski R J ,et al.T-cell invigoration to tumour burden ratio associated with anti-PD-1 response[J].Nature,2017,545(7652):60-5.